Neurocrine (NBIX) has issued an update.
Neurocrine Biosciences, Inc. revealed promising top-line results from a Phase 2 clinical trial of NBI-1117568, a novel oral treatment for schizophrenia, which met its primary endpoint with significant improvements in symptom scores. The medication, which targets the muscarinic M4 receptor, showed a favorable safety profile, with adverse events comparable to placebo. Following these positive outcomes, Neurocrine plans to progress NBI-1117568 into Phase 3 trials, bolstering its portfolio of muscarinic receptor-focused therapies.
For a thorough assessment of NBIX stock, go to TipRanks’ Stock Analysis page.
